Pancreatic adverse events in patients treated with immune checkpoint inhibitors

Abstract Background and Aim The inhibition of cytotoxic T‐lymphocyte associated antigen‐4 (CTLA‐4) and programmed cell death‐1 (PD‐1) has been a target for multiple drugs to enhance the T‐cell antitumor activity. However, these immune checkpoint inhibitors (ICIs) come with a panel of immune‐related...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Caroline Hana, Tauseef Rehman, Kyeeun Park, Carlos Carracedo Uribe, Pyi Phyo Aung, Brian Hunis, Matthew Salzberg, Jennifer Zikria, Atif Hussein
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-03-01
coleção:	JGH Open
Assuntos:	diabetic ketoacidosis immune checkpoint inhibitors immune‐related adverse events pancreatitis
Acesso em linha:	https://doi.org/10.1002/jgh3.12875
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!